Ardena expands nanomedicine capabilities

Sep. 2018

Contract development and manufacturing organisation (CDMO) Ardena has expanded its nanomedicine technology portfolio following a number of investments.

The company now offers a broad range of nanomedicine services, including the development and GMP manufacturing of crystalline nanosuspensions, liposomes, iron oxide nanoparticles and polymeric nanoparticles.  

The service expansion follows Ardena’s recent acquisition of ChemConnection, a leading CDMO of novel active pharmaceutical ingredients (APIs) and nanomedicines.

Alongside the acquisition, Ardena has made significant investments in nanomedicine development and manufacturing capabilities. The CDMO recently invested in an agitator bead mill to support clinical manufacturing of crystalline nanosuspensions, and has also been expanding its use of disposable downstream processing systems to enhance its low-bioburden manufacturing capacity.

Michiel Van Speybroeck, Head of Formulation at Ardena, comments: “Having built up our initial capabilities and expertise around crystalline nanosuspensions, the acquisition of ChemConnection offered an ideal brand synergy, adding an array of technologies and analytical capabilities to advance our existing nano-formulation offering.”

“Our combined services mean our team can now provide drug delivery solutions for even the most difficult-to-formulate compounds emerging from today’s drug discovery pipelines, for example poorly soluble or highly potent APIs.”

The acquisition and addition of new technologies are part of the Belgium-headquartered company’s strategy to form a leading integrated drug development company and reach the €35m sales mark this year. Michiel continued: “We are seeing increasing market demand for nanotechnology and are confident that our expanded capabilities in this area will be of great value to our customers, who will be able to deliver their compounds more effectively.”

Ardena was formed in 2017, following the merging of three companies with complementary drug development capabilities: Pharmavize in Belgium, and Crystallics and Analytical Biochemical Laboratory (ABL) in the Netherlands. With the acquisitions of Netherlands-based ChemConnection and Sweden-based Syntagon in 2018, Ardena now employs more than 225 scientists.

Ardena will be exhibiting at CPhI Worldwide, Madrid, 9 – 11 October 2018 on stand 3A1.

On 9 October at 3.10 PM in the Pharma Insights Workshop Theatre, the Ardena team is also giving a presentation entitled ‘Advancing nanomedicines into the clinic: analytical and manufacturing challenges’ and invites visitors to come along.

For more information, please visit


Press contacts:

Michiel Van Speybroeck
Head of Formulation at Ardena
T +32 9 267 65 00

Eleanor Harms
+44 (0)1912 221 242